CATALYM
Catalym develops antibodies against a placental factor which is overexpressed by various tumour types.
CATALYM
Industry:
Therapeutics
Founded:
2016-01-01
Address:
Munich, Bayern, Germany
Country:
Germany
Website Url:
http://www.catalym.com
Total Employee:
11+
Status:
Active
Contact:
1844 66 34837
Total Funding:
59.33 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Apple Mobile Web Clips Icon WordPress Font Awesome Apache Wordpress Plugins
Similar Organizations
Proteostasis Therapeutics
Proteostasis Therapeutics is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis.
Current Advisors List
Current Employees Featured
Founder
Investors List
Forbion Capital Partners
Forbion Capital Partners investment in Series B - Catalym
Vesalius Biocapital Partners
Vesalius Biocapital Partners investment in Series B - Catalym
BioGeneration Ventures
BioGeneration Ventures investment in Series B - Catalym
Novartis Venture Fund
Novartis Venture Fund investment in Series B - Catalym
coparion
coparion investment in Series B - Catalym
Wachstumsfonds Bayern
Wachstumsfonds Bayern investment in Series B - Catalym
Forbion Capital Partners
Forbion Capital Partners investment in Seed Round - Catalym
Official Site Inspections
http://www.catalym.com
- Host name: sh20024.ispgateway.de
- IP address: 92.205.54.255
- Location: Germany
- Latitude: 51.4476
- Longitude: 7.0122
- Timezone: Europe/Berlin
More informations about "Catalym"
About CatalYm – Catalym
Anne Burger serves as Interim Chief Executive Officer (CEO) and Chief Financial Officer at CatalYm. She brings more than 15 years of experience in financial operations at biotech and medtech companies throughout Europe. She also …See details»
CatalYm - Crunchbase Company Profile & Funding
CatalYm is a biotechnology company committed to developing innovative immunotherapies for cancer patients. CatalYm has identified GDF-15 as a central regulator of the immune system in the tumor microenvironment and translates …See details»
Catalym Company Profile 2024: Valuation, Funding
Catalym General Information Description. Operator of a biopharmaceutical company intended to transform cancer patients' lives by engaging their own immune systems. The company engages in developing antibodies that …See details»
CatalYm GmbH - LinkedIn
CatalYm GmbH | 3,401 followers on LinkedIn. Developing innovative immunotherapies to transform cancer patients’ lives by engaging their own immune systems.See details»
CatalYm GmbH - Drug pipelines, Patents, Clinical trials - Synapse
CatalYm’s series D haul is close to triple its series C total in late 2022, when the biotech raised about $49 million. On the heels of early-stage data for monoclonal antibody visugromab …See details»
Catalym GmbH - Life-Sciences-Europe.com
CatalYm is pioneering a novel immuno-oncology therapy, that safely overcomes GDF-15-mediated immunosuppression in the tumor microenvironment. Our lead product visugromab, a …See details»
CatalYm Company Profile - Office Locations, Competitors ... - Craft
CatalYm is a biopharmaceutical company developing cancer immunotherapies. It develops monoclonal antibodies that enhance the effective infiltration of immune cells into the …See details»
CatalYm - Funding, Financials, Valuation & Investors - Crunchbase
CatalYm is a biotechnology company developing innovative immunotherapies for cancer patients. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. Products. ... How much …See details»
CatalYm - Contacts, Employees, Board Members, Advisors & Alumni
Organization. CatalYm . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies ... About. CatalYm has 5 current employee profiles, …See details»
CatalYm Announces Leadership Change – Catalym
Oct 11, 2024 CatalYm has identified GDF-15 as a key cancer therapy resistance mechanism and is developing it as safe and efficacious immune therapy for solid tumors. GDF-15, an …See details»
CatalYm Announces New Financing of $150M to Support Broad …
MUNICH, July 16, 2024--CatalYm today announced the completion of a $150 million Series D financing. The oversubscribed round was led by new investors, Canaan Partners and Bioqube …See details»
CatalYm Announces New Financing of $150M to ... - Brandon …
Jul 16, 2024 CatalYm is now advancing to Phase 2b studies to confirm visugromab as a new class of cancer immunotherapy in a broad range of anti-cancer regimens. About Visugromab …See details»
CatalYm Closes EUR 50 Million Series C Financing to Expand and ...
Nov 22, 2022 MUNICH--(BUSINESS WIRE)--CatalYm today announced the close of a EUR 50 million (USD 49 million) Series C financing round.The oversubscribed round was co-led by …See details»
News & Events – Catalym
Oct 11, 2024 Follow CatalYm’s journey and learn more about our most recent milestones. October 11, 2024. CatalYm Announces Leadership Change - Read More. July 16, 2024. …See details»
CatalYm raises $150m for cancer therapy visugromab
Jul 18, 2024 CatalYm has completed a $150 million Series D financing to support the Phase II development of its cancer therapy visugromab. The oversubscribed round was led by new …See details»
CatalYm Commences Phase 2 Development of GDF-15-Targeting …
Mar 1, 2022 CatalYm receives International Nonproprietary Name (INN) visugromab for CTL-002 as approved by the World Health Organization; Munich, Germany, March 01, 2022 – CatalYm …See details»
CatalYm Receives FDA IND Clearance to Expand ... - Business Wire
Sep 26, 2022 About CatalYm CatalYm has identified GDF-15 as a central regulator of the immune system in the tumor microenvironment. We are pioneering the reversal of GDF-15 …See details»
Science - Catalym
Aug 30, 2021 CatalYm and its collaborators have identified GDF-15 as a key regulator in cancer therapy resistance by unraveling the underlying pathways contributing to immune evasion, …See details»
CatalYm Announces New Financing of $150M to Support Broad …
Jul 16, 2024 CatalYm is now advancing to Phase 2b studies to confirm visugromab as a new class of cancer immunotherapy in a broad range of anti-cancer regimens. About Visugromab …See details»